Federal Policy
FDA Approves Gene Therapy for Children with Sickle Cell Disease
The FDA has approved a new gene therapy treatment for children aged 2 and older with sickle cell disease. The approval expands treatment options for pediatric patients with this serious inherited blood disorder, which disproportionately affects Medicaid beneficiaries. Sickle cell disease affects approximately 100,000 Americans, with the majority covered by Medicaid. Managed care organizations will need to evaluate coverage policies, establish prior authorization criteria, and assess the financial impact of this high-cost specialty therapy on capitation rates and medical loss ratios.
Why it mattersGene therapies for sickle cell disease can cost $2-3 million per patient, creating significant financial exposure for Medicaid MCOs with pediatric populations and requiring immediate attention to coverage determinations, utilization management protocols, and rate adequacy discussions with state Medicaid agencies.